Novo Nordisk: diabetes drug reduces cardiovascular risk
(CercleFinance.com) - Novo Nordisk's Ozempic consistently reduced the risk of cardiovascular events in people with type-2 diabetes, post-hoc analyses showed.
Findings from several phase 3 trials presented at the European Society of Cardiology congress in Munich found that Ozempic reduced the risk of non-fatal heart attack, non-fatal stroke or cardiovascular death, the Danish drugmaker said.
Cardiovascular disease remains the leading cause of disability and death in people with type-2 diabetes, Novo said.
Ozempic was approved by the US Food and Drug Administration in December 2017, followed by the European Commission in February 2018.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Findings from several phase 3 trials presented at the European Society of Cardiology congress in Munich found that Ozempic reduced the risk of non-fatal heart attack, non-fatal stroke or cardiovascular death, the Danish drugmaker said.
Cardiovascular disease remains the leading cause of disability and death in people with type-2 diabetes, Novo said.
Ozempic was approved by the US Food and Drug Administration in December 2017, followed by the European Commission in February 2018.
Copyright (c) 2018 CercleFinance.com. All rights reserved.